Details of the Drug

General Information of Drug (ID: DMHT34O)

• Drug Name: Gemifloxacin
• Synonyms: Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[2]
Streptococcal pneumonia	N.A.	Approved	[2]
Pneumonia caused by chlamydia	N.A.	Investigative	[2]
Pneumonia due to Klebsiella pneumoniae	CA40.03	Investigative	[2]

• Therapeutic Class: Antibiotics
• Affected Organisms: Enteric bacteria and other eubacteria
• ATC Code:
  J01MA15: Gemifloxacin
  J01MA: Fluoroquinolones
  J01M: QUINOLONE ANTIBACTERIALS
  J01: ANTIBACTERIALS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
  J01MA15: Gemifloxacin
  J01MA: Fluoroquinolones
  J01M: QUINOLONE ANTIBACTERIALS
  J01: ANTIBACTERIALS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 389.4
  Logarithm of the Partition Coefficient (xlogp); -0.7
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 10
• ADMET Property:
  Bioavailability: The bioavailability of drug is 71% []
  Clearance: The renal clearance of drug is 11.6 +/- 3.9 L/h []
  Half-life: The concentration or amount of drug in body reduced by one-half in 7 +/- 2 hours [3]
  Metabolism: The drug is metabolized via the liver []
  Unbound Fraction: The unbound fraction of drug in plasma is 0.3% [3]
  Vd: The volume of distribution (Vd) of drug is 1.66-12.12 L/kg []
• Chemical Identifiers:
  Formula: C18H20FN5O4
  IUPAC Name: 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
  Canonical SMILES: CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
  InChI: InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
  InChIKey: ZRCVYEYHRGVLOC-HYARGMPZSA-N
• Cross-matching ID:
  PubChem CID: 9571107
  ChEBI ID: CHEBI:101853
  CAS Number: 175463-14-6
  UNII: OKR68Y0E4T
  DrugBank ID: DB01155
  TTD ID: D0VR7W
  VARIDT ID: DR00688
  ACDINA ID: D00301
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU ; GYRB_STAAU	Modulator	[4]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[5]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Gemifloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[6]

Coadministration of a Drug Treating the Disease Different from Gemifloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[7]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[6]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[8]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Oliceridine.	Acute pain [MG31]	[6]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Ivabradine.	Angina pectoris [BA40]	[8]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Bepridil.	Angina pectoris [BA40]	[10]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Dronedarone.	Angina pectoris [BA40]	[11]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[6]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Posaconazole.	Aspergillosis [1F20]	[6]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Levalbuterol.	Asthma [CA23]	[12]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Pirbuterol.	Asthma [CA23]	[13]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[8]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Retigabine.	Behcet disease [4A62]	[6]
Lomustine	DMMWSUL	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[14]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[11]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[6]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[6]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[15]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[12]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Mestranol	DMG3F94	Moderate	Decreased absorption of Gemifloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[16]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Halothane.	Corneal disease [9A76-9A78]	[6]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[11]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Probucol.	Coronary atherosclerosis [BA80]	[6]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Pasireotide.	Cushing syndrome [5A70]	[11]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Osilodrostat.	Cushing syndrome [5A70]	[8]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Escitalopram.	Depression [6A70-6A7Z]	[11]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Clomipramine.	Depression [6A70-6A7Z]	[6]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[11]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Gemifloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[17]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Ingrezza.	Dystonic disorder [8A02]	[18]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Solifenacin.	Functional bladder disorder [GC50]	[6]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[6]
Procarbazine	DMIK367	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[14]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[6]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[20]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[11]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[11]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Crizotinib.	Lung cancer [2C25]	[21]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Ceritinib.	Lung cancer [2C25]	[11]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[14]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Osimertinib.	Lung cancer [2C25]	[22]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Selpercatinib.	Lung cancer [2C25]	[8]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lumefantrine.	Malaria [1F40-1F45]	[23]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Halofantrine.	Malaria [1F40-1F45]	[24]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[25]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[8]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[26]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Vemurafenib.	Melanoma [2C30]	[11]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and LGX818.	Melanoma [2C30]	[27]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Gemifloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[11]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Panobinostat.	Multiple myeloma [2A83]	[28]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Siponimod.	Multiple sclerosis [8A40]	[23]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Fingolimod.	Multiple sclerosis [8A40]	[11]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Ozanimod.	Multiple sclerosis [8A40]	[29]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Deflazacort.	Muscular dystrophy [8C70]	[30]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Romidepsin.	Mycosis fungoides [2B01]	[6]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[11]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[6]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Gemifloxacin and Bupropion.	Nicotine use disorder [6C4A]	[31]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[23]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[8]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lofexidine.	Opioid use disorder [6C43]	[11]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Rucaparib.	Ovarian cancer [2C73]	[6]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[6]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Pimavanserin.	Parkinsonism [8A00]	[32]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[33]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lefamulin.	Pneumonia [CA40]	[34]
Choline salicylate	DM8P137	Moderate	Additive CNS depression effects by the combination of Gemifloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[35]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Degarelix.	Prostate cancer [2C82]	[8]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and ABIRATERONE.	Prostate cancer [2C82]	[8]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Enzalutamide.	Prostate cancer [2C82]	[8]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Relugolix.	Prostate cancer [2C82]	[8]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[6]
Salsalate	DM13P4C	Moderate	Additive CNS depression effects by the combination of Gemifloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[35]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[30]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Quetiapine.	Schizophrenia [6A20]	[11]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Aripiprazole.	Schizophrenia [6A20]	[23]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Iloperidone.	Schizophrenia [6A20]	[11]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Amisulpride.	Schizophrenia [6A20]	[36]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Asenapine.	Schizophrenia [6A20]	[11]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[14]
Docetaxel	DMDI269	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[14]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[14]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[6]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[11]
Taxol	DMUOT9V	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[14]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Pitolisant.	Somnolence [MG42]	[8]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[6]
Plicamycin	DM7C8YV	Minor	Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Plicamycin.	Testicular cancer [2C80]	[14]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Lenvatinib.	Thyroid cancer [2D10]	[6]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Gemifloxacin and Cabozantinib.	Thyroid cancer [2D10]	[8]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[6]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[6]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Gemifloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[6]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Crospovidone	E00626	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Gemifloxacin 320 mg tablet	320 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [2] Gemifloxacin FDA Label
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
• [6] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [7] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [8] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [9] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [10] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [11] Canadian Pharmacists Association.
• [12] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [13] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [14] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [15] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [16] Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
• [17] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [18] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [19] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [20] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
• [21] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [22] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [23] Cerner Multum, Inc. "Australian Product Information.".
• [24] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [25] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [26] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [27] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [28] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [30] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
• [31] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [32] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [33] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [34] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [35] Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
• [36] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.